Alvimopan
- Generic Name
- Alvimopan
- Brand Names
- Entereg
- Drug Type
- Small Molecule
- Chemical Formula
- C25H32N2O4
- CAS Number
- 156053-89-3
- Unique Ingredient Identifier
- Q153V49P3Z
- Background
Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.
- Indication
用于手术以及使用阿片类药物导致的胃肠功能紊乱，特发性便秘以及肠易激综合症等。
- Associated Conditions
- -
- Associated Therapies
- Gastrointestinal Recovery
Accelerating Gastrointestinal Recovery
- Conditions
- Interventions
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Jamie N. Bakkum-Gamez
- Target Recruit Count
- 146
- Registration Number
- NCT01704651
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Entereg Laparoscopic Colon Resection Study
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT01258569
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database
- First Posted Date
- 2010-06-25
- Last Posted Date
- 2015-08-07
- Target Recruit Count
- 7050
- Registration Number
- NCT01150760
- Locations
- 🇺🇸
Premier database, Charlotte, North Carolina, United States
A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2016-01-08
- Target Recruit Count
- 280
- Registration Number
- NCT00708201
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸The Methodist Hospital, Houston, Texas, United States
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
- Conditions
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2015-07-20
- Target Recruit Count
- 510
- Registration Number
- NCT00388401
- Locations
- 🇺🇸
Adolor Corporation, Exton, Pennsylvania, United States
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
- Conditions
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2017-08-22
- Target Recruit Count
- 451
- Registration Number
- NCT00388258
- Locations
- 🇺🇸
Various, Exton, Pennsylvania, United States
Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus
- Conditions
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2015-07-20
- Target Recruit Count
- 666
- Registration Number
- NCT00388479
- Locations
- 🇺🇸
Various, Exton, Pennsylvania, United States
Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid
- Conditions
- Interventions
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2015-09-02
- Target Recruit Count
- 21
- Registration Number
- NCT00331045
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
- Conditions
- Interventions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2015-09-02
- Target Recruit Count
- 485
- Registration Number
- NCT00259922
- Locations
- 🇨🇭
GSK Investigational Site, Nottwil, Switzerland
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2015-09-02
- Target Recruit Count
- 518
- Registration Number
- NCT00256932
- Locations
- 🇬🇧
GSK Investigational Site, York, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.